Triple negative phenotype and N-ratio are important for prognosis in patients with stage IIIB non-inflammatory breast carcinoma

Journal of Surgical Oncology

Volumn 100, Issue 8, 2009, Pages 681-687

  Mersin, Hakan ^a   Yildirim, Emin ^b   Berberoglu, Ugur ^a   Gulben, Kaptan ^a  

^a ANKARA ONCOLOGY EDUCATION AND RESEARCH HOSPITAL   (Turkey)

^b BOZOK UNIVERSITY   (Turkey)

Author keywords

Breast carcinoma; Distant recurrence; Local recurrence; Prognosis; Stage IIIB; Survival

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER INVASION; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; FEMALE; HAZARD RATIO; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; TUMOR GROWTH; TUMOR VOLUME; UNIVARIATE ANALYSIS;

ADULT; AGED; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PHENOTYPE; PROGNOSIS; RETROSPECTIVE STUDIES;

EID: 73449117892     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21411     Document Type: Article

References (47)

1. Nahleh Z, Sivasubramanian D, Dhaliwal S, et al.: Residual cancer burden in locally advanced breast cancer: A superior tool. Curr Oncol 2008;15:271-278.
2. Cianfrocca M, Goldstein LJ: Prognostic and predictive factors in early-stage breast cancer. Oncologist 2004;9:606-616.
3. Sheldon DG: Beyond lymph node staging: Molecular predictors of outcome in breast cancer. Surg Clin North Am 2005;14:69-84.
4. Yildirim E, Berberoglu U: Lymph node ratio is more valuable than level III involvement for prediction of outcome in nodepositive breast carcinoma patients. World J Surg 2007;31:276-289.
5. Vinh-Hung V, Verkooijen HM, Fioretta G, et al.: Lymph node ratio as an alternative to pN staging in node-positive breast cancer. J Clin Oncol 2009;27:1062-1068.
6. Rakha EA, El-Sayed ME, Green AR, et al.: Prognostic markers in triple-negative breast cancer. Cancer 2007;109:25-32.
7. Mersin H, Yildirim E, Berberoglu U, et al.: The prognostic importance of triple negative breast carcinoma. Breast 2008;17: 341-346.
8. Greene FL, Page FL, Fleming DL, et al., editors: AJCC cancer staging manuel. New York, NY: Springer-Verlag; 2002.
9. Hayward JL, Carbone PP, Henson JC, et al.: Assessment of response to therapy in advanced breast cancer. Eur J Cancer 1977;13:89-94.
10. Bloom HJG, Richardson VW: Histologic grading and prognosis in breast cancer. Br J Cancer 1957;11:359-377.
11. Troung PT, Yong CM, Abnousi F, et al.: Lymphovascular invasion is associated with reduced locoregional control and survival in women with node negative breast cancer treated with mastectomy and systemic therapy. J Am Coll Surg 2005;200:912-921.
12. Hudis CA, Barlow WE, Costantino JP, et al.: Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system. J Clin Oncol 2007;25:2127-2132.
13. Kaplan EL, Meier P: Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958;53:457-481.
14. Cox DR: Regression models and life tables. J R Stat Soc 1972;B34:187-220.
15. Kleinbaum DG, Kupper LL, Muller KE, et al., editors: Applied regression analysis and other multivariable methods, 3rd edition. Pacific Grove, CA: Brooks/Cole; 1998.
16. Hanley JA, McNeil BJ: The meaning and use of the area under a receiver characteristic (ROC) curve. Radiology 1982;143:29-36.
17. Youden WJ: Index for rating diagnostic tests. Cancer 1950;3:32-35.
18. Mathew J, Asgeirsson KS, Agrawal A, et al.: Neoadjuvant chemotherapy in locally advanced primary breast cancers-The Nottingham experience. Eur J Surg Oncol 2007;33:972-976.
19. Lee MC, Newman LA: Management of patients with locally advanced breast cancer. Surg Clin North Am 2007;87:379-398.
20. Yildirim E, Semerci E, Berberoglu U: The analysis of prognostic factors in stage III-B non-inflammatory breast cancer. Eur J Surg Oncol 2000;26:34-38.
21. Gajdos C, Tartter PI, Estabrook A, et al.: Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer. J Surg Oncol 2002; 80:4-11.
22. Brenner B, Siris N, Rakowsky E, et al.: Prediction of outcome in locally advanced breast cancer by post-chemotherapy nodal status and baseline serum tumour markers. Br J Cancer 2002;87:1404-1410.
23. Shen J, Valero V, Buchholz TA, et al.: Effective local control and long term survival in patients with T4 locally advanced breast cancer treated with breast conservation therapy. Ann Surg Oncol 2004;11:854-860.
24. Loya A, Guray M, Hennessy BT, et al.: Prognostic significance of occult axillary lymph node metastases after chemotherapy induced pathologic complete response of cytologically proven axillary lymph node metastases from breast cancer. Cancer 2009; 115:1605-1612.
25. Kuerer HM, Newman LA, Smith TL, et al.: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol 1999;17:460-469.
26. Bear HD, Anderson S, Smith RE, et al.: Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2006;24:2019-2027.
27. McIntosh SA, Ogston KN, Payne S, et al.: Local recurrence in patients with large and locally advanced breast cancer treated with primary chemotherapy. Am J Surg 2003;185:525-531.
28. Clouth B, Chandrasekharan S, Inwang R, et al.: The surgical management of patients who achieve a complete pathological response after primary chemotherapy for locally advanced breast cancer. Eur J Surg Oncol 2007;33:961-966.
29. Giordano SH: Update on locally advanced breast cancer. Oncologist 2003;8:521-530.
30. Keam B, Im SA, Kim HJ, et al.: Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: Paradoxical features of the triple negative breast cancer. BMC Cancer 2007;7:203.
31. Kai K, Miyayama H, Yamamoto Y, et al.: Pathological lymph node involvement at surgery is a significant predictive factor of recurrence in locally advanced breast cancer treated with concomitant epirubicin-docetaxel neoadjuvant chemotherapy: A cohort study. Breast Cancer 2009;16:42-448.
32. Hennessy B, Hortobagyi G, Rouzier R, et al.: Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. J Clin Oncol 2005;23:9304-9311.
33. Guarneri V, Broglia K, Kau SW, et al.: Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J Clin Oncol 2006;24:1037-1044.
34. Kuerer HM, Sahin AA, Hunt KK, et al.: Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy. Ann Surg 1999;230:72-78.
35. Kuerer HM, Newman LA, Buzdar AU, et al.: Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease free survival in patients with locally advanced breast cancer. Am J Surg 1998;176:502-509.
36. Neuman H, Carey LA, Ollila DW, et al.: Axillary lymph node count is lower after neoadjuvant chemotherapy. Am J Surg 2006;191:827-829.
37. Vinh-Hung V, Verschraegen C, Promish DI, et al.: Ratios of involved nodes in early breast cancer. Breast Cancer Res 2004;6: R680-R688.
38. van der Wal BCH, Butzelaar RMJM, van der Meij S, et al.: Axillary lymph node ratio and total number of removed lymph nodes: Predictors of survival in stage I and II breast cancer. Eur J Surg Oncol 2002;28:481-489.
39. Voordeckers M, Vinh-Hung V, Van de Sten J, et al.: The lymph node ratio as prognostic factor in node positive breast cancer. Radiother Oncol 2004;70:225-230.
40. Costa LJM, Soares HP, Gaspar HA, et al.: Ratio between positive lymph nodes and total dissected axillaries lymph nodes as an independent prognostic factor for disease free survival in patienst with breast cancer. Am J Clin Oncol 2004;27:304-306.
41. Truong PT, Berthelet E, Lee J, et al.: The prognostic significance of the percentage of positive/dissected axillary lymph nodes in breast cancer recurrence and survival in patients with one to three positive axillary lymph nodes. Cancer 2005;103:2006-2014.
42. Truong PT, Woodward WA, Thames HD, et al.: The ratio of positive to excised nodes identifies high-risk subsets and reduces inter-institutional differences in locoregional recurrence risk estimates in breast cancer patients with 1-3 positive nodes: An analysis of prospective data from British Columbia and the M.D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys 2007;68: 59-65.
43. 1-2 and 1-3 positive nodes: Indications for radiotherapy. Eur J Surg Oncol 2007;33:28-32.
44. Huang EH, Tucker SL, Strom EA, et al.: Predictors of locoregional recurrence in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy, mastectomy, and radiotherapy. Int J Radiat Oncol Biol Phys 2005;62:351-357.
45. Haffty BG, Yang Q, Reiss M, et al.: Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol 2006;24:5652-5657.
46. Freedman GM, Anderson PR, Li T, et al.: Locoregional recurrence of triple negative breast cancer after breast conserving surgery and radiation. Cancer 2009;115:946-951.
47. Kim M-J, Ro JY, Ahn S-H, et al.: Clinicopathologic significance of the basal-like subtype of breast cancer: A comparison with hormone receptor and Her2/neu-overexpressing phenotypes. Hum Pathol 2006;37:1217-1226.